TNFRSF1B and neoplasm: Our study provides evidence that TNFR2 antagonistic antibody can enhance the antitumor immunity in combination with anti-PD-L1 treatment in breast cancer by negatively affecting the accumulation of Tregs and increasing the percentage of Teff cells in tumor tissues.